GeoVax Secures Funding Through Warrant Transaction to Advance Vaccine and Cancer Therapy Programs

GeoVax Labs, Inc., a clinical-stage biotechnology company, announced a warrant inducement transaction with existing healthcare-focused institutional investors that will provide immediate funding for its development programs. The agreement involves the immediate exercise of existing warrants to purchase up to 634,658 shares of common stock at a reduced exercise price of $1.36, generating gross cash proceeds of approximately $863,000 before deducting financial advisor fees and other transaction expenses. The company intends to use the net proceeds for working capital and other general corporate purposes, which is crucial for advancing its pipeline of medical innovations.

In consideration for the immediate exercise of existing warrants, investors will receive new unregistered warrants to purchase up to 1,269,316 shares of common stock through a private placement. These new warrants will have the same exercise price of $1.36 and will become exercisable once shareholder approval is obtained, expiring five years following that approval date. The transaction is expected to close on or about April 1, 2026, subject to customary closing conditions. This financial maneuver demonstrates how biotechnology companies utilize complex financing structures to secure necessary capital while maintaining investor relationships during critical development phases.

The private placement of new warrants and underlying shares will be made in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, meaning these securities cannot be offered or sold in the United States without an effective registration statement or applicable exemption. This transaction occurs as GeoVax advances multiple clinical programs, including its priority GEO-MVA vaccine targeting mpox and smallpox, which is progressing under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026. The company's development pipeline addresses significant global health needs, including orthopoxvirus vaccine supply and biodefense preparedness, making this funding particularly timely.

In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity, which has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies. The company's broader pipeline includes GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. These programs represent important advancements in both infectious disease prevention and cancer treatment, areas where medical innovation can significantly impact public health outcomes. The warrant transaction provides essential capital to continue these developments without immediate dilution concerns that might accompany traditional equity offerings.

The importance of this announcement lies in its demonstration of how biotechnology companies navigate financial markets to fund critical research while managing shareholder value. For more information about GeoVax's programs, visit https://www.geovax.com. The funding comes at a pivotal time as the company prepares for advanced clinical trials and potential regulatory submissions, with the capital supporting continued operations and research activities. This transaction reflects investor confidence in GeoVax's technology platform and development strategy, particularly as the company addresses both immediate infectious disease threats and longer-term cancer therapy needs through its diversified pipeline approach.